Seeking Alpha
01 Jul 2026, 15:05 UTC · 2h ago
TransMedics: The Margins Must Recover
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
01 Jul 2026, 15:05 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
TransMedics' Q1 gross margin fell to 58.2% and adjusted EPS dropped to $0.30. — Direct evidence of margin pressure and earnings decline typically triggers short-term sell-offs in growth stocks.
-0.60Q1 revenue grew 21% to $173.9M. — Consistent double-digit top-line growth supports the long-term growth thesis despite short-term profit dips.
+0.40The company is building an integrated transplantation network to establish long-term market dominance. — The creation of a competitive moat suggests sustainable future pricing power and market share.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The article maintains a Buy rating and emphasizes a strong long-term growth thesis and moat despite short-term margin pressure.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
24/7 Wall Street
4h ago
